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Dexamethasone Suppression Test in Schizophrenia: 
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Rajiv Tandon, Che~l Mazzara, John !)eQ~ardo, 
Katherine A. Craig, James H. Meador-Woodruff, 
Robert Goldman, and John F. Greden 
To relieve confusion about the clinical correlates and prognostic implications of the 
dexamethasone suppression test (DST) in schizophrenia, we conducted a DST in 44 
schizophrenic inpatients at drug-free baseline and approximately 4 weeks after neuroleptic 
treatment. Patients were rated on positive, negative, and depressive symptoms at both 
times. A head computed tomography (CT) scan was ?: elformed and measures of ventricle- 
brain ratio (VBR) obtained. Clinical improvement was monitored at four weeks, and 
longer-term outcome assessed at I year. Seventeen of the 44 paiients were DST nonsup- 
pressors at baseline, and five of  these remained nonsuppressors at 4 weeks posttreatment. 
Postdexamethasone plasma cortisol levels were correlated with negative ~ymptoms at 
baseline (r = 0.45; p < 0.0] ), but not after 4 weeks of neuroieptic treatment. Postdex- 
amethasone plasma cortisols we.~e not related to global severity, positive, or depressive 
symptoms at either timepoint or to VBR. Persistent nonsuppression was associated with 
poor outcome, but baseline postdexamethasone cortisol levels were unrelated to outcome 
at 4 weeks and I year. The literature on DST in schizophrenia is reviewed and attempts 
are made to reconcile discrepant findings and to discuss pathophysiological implications. 
Introduction 
Although the dexamethasone suppression test (DST) was originally proposed as a specific 
marker for major depressive disorder (Carroll et al 1981), studies in schizophrenia have 
yielded rates of  nor, suppression ranging from 0% to 73% (Yeragani 1990). Higher rates 
ol DST nonsuppression in schizophrenia have been attributed to depressive symptoms 
(Munro et al 1984; Sawyer and Jeffries 1984), negative symptoms (Coppen et al t983; 
Shima et al 1986; Tandon et al 1989a), and the nonparanoid subtype (Banki et al 1984). 
tt also has been suggested that DST nonsuppression in schizophrenia may prognosticate 
a better outcome (Targum 1983; Coryell and Zimmerman 1989). Most o f  these findings 
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have not, however, been confirmed in other investigations and the approximately 50 
studies of DST in schizophrenia have yielded disc~epant findings. 
The present study was conducted in an effort to define the clinical correlates and 
prognostic implications of the DST response in s~hizophrenia, and study the impact of 
phase of illness, neuroleptic treatment, and ventricular size. In a preliminary report 
(Tandon et al 1989a), we had observed a 35% nonsuppression rate in a sample of 20 
medication-free schizophrenic patients, and an association between postdexamethasone 
cortisol levels and severity of negative symptoms. We now report findings on an expanded 
sar~ple of 58 patients with regard to frequency of DST nonsuppression in medication- 
fret. and neuroleptic-treated phases of schizophrenic illness, and relationship of the DST 
response to symptomatology (positive, negative, and depressive symptoms). In this study, 
we additionally investigated the relationship c,f the DST response to ventricular size and 
l-year outcome. 
Methods  
The original sample consisted of 58 consecutively hospitalized patients who were admitted 
to the Inpatient Schizophrenia Program at the University of Michigan from 1987-1989. 
All patients met DSM-III-R (American Psychiatric Association 1987) and Research Di- 
agnostic Criteria (RDC) (Spitzer et al 1978) for schizophrenia. Patients with any medical 
criteria known to interfere with a valid DST (Carrt, ll et al 1981) were excluded. No 
patient had received depot neuroleptics for at least 6 months before entering the study. 
Informed consent was obtained. After patients had been drug-free for a minimum of 2 
weeks, clinical ratings, head computed tomegraphy (CT) scan, and a 1 mg DST were 
performed. Patients were then treated with clinically determined doses of haloperidol, 
thiothixene, or chlerpromazine [doses of 8-30 mg haloperidol equivalents per day (Bal- 
dessarini 1984)], singly or in combination with 2-6 mg of trihexyphenidyl. After about 
4 weeks of such treatment, clinical ~atings and the DST were repeated. Approximately 
1 year after the initial drug-free evaluation, outcome was assessed. Outcome could be 
assessed on 44 of the 58 patients in the original sample.. The remaining patients could 
not be located. All subjects who had clinical ratings and a valid DST at the drug-free 
and 4-week posttreatment timepoints, and on whom outcome could be assessed at 1 year 
were included in the final sample. The final sample of 44 patients consisted of 29 men 
and 15 women, with a mean (--+SD) age of 29 (---8) years (range 18-46 years). The 
mean duration of the illness was 7 ( __. 5) years. Of these 44 patients, 15 we~ drug naive 
(never medi~:ated), ~2 had been noncompliant with prescribed treatment and were drug 
free for >4 weeks, and 17 were drug free for 2--4 weeks. 
Patients were rated by one of the investigators (RT) on the l~-item Brief Psychiatric 
Rating Scale [BPRS (Overall and Gorham 1962)], Scale for the Assessment of Negative 
Symptoms [SANS (Andreasen 1983)], and the tIamilton Depression Rating Scale [HDRS 
(H~unilton 1960ji at baseline and about 4 weeks after neuroleptic treatment. Ratings were 
completed while blind to DST results and head CT findings. Global severity was assessed 
by the 18-i:em BPRS total score. Positi~;e symptom severity was assessed by the gum of 
thf following four BPRS items: conceptual disorganization, suspiciousness, hallucinatory 
~havier, and unusual thought content. Collectively, these items comprise the BPRS 
"THOT" factor (Guy 1976; Hedlund and Vieweg 1980) and are most c~mmonly employed 
to rate positive symptoms. Negative symptoms were assessed by ~ e  SANS, the sum of 
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global scores being emplo.~ ed Ks the measure of negative symptom severity. The BPRS 
"ANER" factor, consisting of emotional withdrawal, motor retardation, and blunted affect, 
was utilized for comparison. Depressive symptom severity was assessed by the 17-item 
HDRS total score. Change in symptom ratings at 4 weeks was employed as the measure 
of improvement at 4 weeks. 
A l-rag DST (Carroll et al 1981) was performed at drug-free baseline and after about 
4 weeks of neuroleptic trea,~nent. The first DST was performed at least 1 week after the 
patient's hospital admission to permit adaptation (Haskett et al 1989). Clinical ratings 
and the corresponding DST were peffo:-cned within 2 day ~, of each other. Blood samples 
for postdexamethasone cortisol levels were obtained at 4 PM and 11 aM and the t~aaximal 
cortisol levels were employed for analysis. C~ i so l  was assayed by Murphy's competitive 
protein-binding method (Murphy 1967). Maximal postdexamethasone cortisol levels > 
5 ~g/dl have been established in our clinical setting to be indicative of nonsuppression 
(Carroll et al 1981). Plasma dexamethasone levels were not measured in this study. 
A head CT scan was performed on 36 of the 44 patients in the sample and measures 
of ventricle-brain ratio (VBR) obtained by videoscreen plaJ,Ametry. Two raters (JD and 
JMW), blind to clinical ratings and DST findings, coilducted these measurements and 
the mean of two ratings of the maximum VBR on the CT braiz~ slices ( L V B R ~ )  on 
each individual patient was employed for analysis. 
Outcome was assessed by the Strauss-Carpenter scale (Strauss and Carpenter 1972; 
McGlashan 1984), on which hospitalization, employment, social activity: symptoms, 
global function, and compliance are all assessed on a 5-point (0--4) scale. A family 
member/careprovider, and the individual's treating psychiatrist or community mental 
he~t,h center casemanager were contacted for this assessment by two independent raters 
(CM and KC) about 1 year after the initial drug-free evaluation. After their independent 
assessments, a joint conference was held between these raters to arrive at final consensus 
ratings. The raters were blind to the clinical ratings, DST, and head CT findings. 
The relationship between DST findings and other parameters was evaluated by cal- 
culating Pearson's product-moment correlations between leg-transformed maximal post- 
dexar, ethasone cortisol levels and clinical ratings, VBR, and outcome measures. Based 
on DST suppression/nonsuppression at the two timepoints, patients were then divided 
into the following three groups: patients who were suppressive following dexamethasone 
at both timepoiets (S-S); patients who were nonsuppressive at drug-free baseline but who 
eonvelxed .to normal suppression after 4 weeks (NS-S); and those who continued to be 
nonsuppressors even after 4 weeks of neuroleptic treatment (NS-NS). These groups were 
compared on clinicai" ratings, VBR, and outcome by analysis of variance (ANOVA). 
Resul ts  
In the total ~ample, at drug-free baseline, postdexamethasone cortisol levels were sig- 
nificant!y correlated with negative symptom scores measured either by the SANS (r = 
0.45; n = 44; p < 0.01) or the BPRS "ANER" factor (r = 0.41;p < 0.0I). F~gure 1 
i~Austrates the relationship between baseline postdexamethasone cortisol and the SANS 
sum of global scores. Baseline postde×amethasone co~isol levels were significantly cor- 
related to four SANS subscale global scores (r = 0.39--9.49; p < 0.05 for affective 
blunting, avolition--apathy, anhedonia-asociality, and attentional impairment) and showed 
a trend toward significant relationship with the alogia subscale global score (r = 0.31; 
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2 2 5  r = 0,45 
~' N = 44 
20~ p< 0.01 
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Figure I .  Association between postdex cortisol and negative symptoms (r = 0.45; n = 44; p < 
0.01). 
p < 0.10). There was no relationship to global severity (r  = 0.20; NS), positive symptoms 
(r = 0.20; NS), or depressive symptoms (r  = 0.17; NS). Similarly, baseline postdex- 
amethasone co,tisol levels were unrelated to age, sex, VBR, improvement of symptoms 
at 4 weeks, or any index of outcome at 1 year. (Similar imdings were obtained when the 
larger sample of 58 patients, including 14 on whom outcome data not available, was 
considered.) ,'ostdexamethasone cortisol levels were significantly correlated to change in 
SANS sum of global scores during neuroleptic treatment (r  = 0.38; p < 0.05). 
At the 4-wee~ posttreatment timepoint, postdexamethasone cordsol levels were un- 
related to negative symptoms (r  = 0.13; NS), positive symptoms (r  = 0.15; NS), 
depressive symptoms (r = 0.13; NS), or global severity (r  = 0.23; NS). There also 
was no asseciation with age, sex, VBR, or outcome at 1 year. Drug-free and 4-week 
posttreatment postdexamethasone cortisol levels were significantly correlated (r  = 0.42; 
p < 0.01). 
The BPRS total (mean _+ SD) o~t the entire sample at medication-free baseline was 
49 ( -- 7.5). The mezal severity of positive symptoms (measured by the BPRS "THOT" 
subscale) and negative symptoms (measured by the SANS sum of global scores) were 
t5.7 (_+ 3.0) and 13.2 ( _  3.9) respectively. Both posltivc and negative symptoms im- 
proved with neuroleptic treatment; the mean positive and negative symptom severity at 
4-weeks posttreatment were 9.5 ( -+ 3.1) and 8.8 ( -+ 3.9) respectively. The mean maximal 
postdexamethasone cortisol was 5.5 (+-_ 5.0) at drug-free baseline and 2.6 (--2.6)  at 4- 
weeks posttreatment. Head CT scans from 36 patients resuRed in a mean -+ SD LVBR~.ax 
of 0.08 ( +- 0.03). 
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S~'1enteen of the a4 patients ¢39%) were DST nor, suppressors at baseline, including five 
of 15 previously never-medicated patients, in the larger sample of 58 patients, 22 were non- 
suppressors, yielding a similar nonsuppression rate of 38% at drug-free baseline. Although 
all patients were drug-free t0r at least 2 weeks before the initial DST, Kxaus et al (1988) 
have suggested that w:xhdrawal of neuroleptics-anticholinergics may produce DST non- 
suppression lasting up to 21 days. Analysis of the data to examine for this possibility re- 
vealed that in our final sample, 15 patients were drag naive, 12 patients were drug free >4  
weeks, and 17 patients were drug free for 2-4  weeks. Five of the t5 drug-naive patients 
(33%), five of the 12 patients drag free > 4  weeks (42%), and seven of the i7 patients drug 
free for 2-4  weeks (41%) were DST nonsuppressors. Thus, psychotropic withdrawal ef- 
fects apparently did not account for the DST f~ndings obse~-cd in our study. 
Of the 17 baseline DST nonsuppressors 12 became normally suppressive (NS-S) at 4- 
weeks posttreatment. Gi  the 27 patients who were DST suppressors at drug-free baseline, 
26 remained suppressive (S-S), while one became a DST nonsuppressor at 4-weeks 
posttreatment. This patient was classified with the five pers stent DST nonsuppressors in 
the NS-NS group. The three groups are compared on symptom ratings, VBR, and outcome 
in Table 1. The three groups did not differ in age or sex ¢ stsSbufion. While there was 
no statistical difference in maximal VBR between the three groups, persistent DST 
nonsuppressors tended to have larger VBR (F = 1.8; df = 2,33; F < 0~19). 
At drug-free baseline, ,,he three groups did not differ with regard to severity of positive 
symptoms, depression, or global severity. Both persistent DST non~uppressors and nor- 
malizing DST nonsuppressors had significantly higher negative symptom scores than the 
persistent DST suppressor group. By definition, both the DST nonsuppressor groups had 
significantly higher postdexamethasone cortisol levels than the DST suppressor group. 
After 4 weeks of clinically determined neuroleptic treatment, the three groups did not 
differ with regard to severity of positive symptoms, depression, or global severity. The 
persistent DST nonsupyressor group had significantly higher negative symptom ratings 
than the persistent DST suppressor and normalizing DST nonsuppressor (suppressor at 
this timepoint) groups. Again by definition, the persistent DST nonsuppressor group had 
higher mem~ postdexamethasone cortisol than the other two groups. 
After 4 weeks of neuroleptic treatment, the normalizing DST nozsuppressor group 
showed significantly greater improvement in both negative symptoms and global severity 
than the other two groups. There were no differences ~ tween the three groups with 
regard to degree of improvement of positive or depressive symptoms. 
There were significant differences between the three groups with regard to l-year 
outcome. The persistent DST nonsuppressor group had significantly worse total outcome 
than thc other two groups. While the normalizing DST nonstlppr~ "~r group had somewhat. 
b:,tter o~tcome than the persistent DST suppressor group, this di~,~,ence was not statiso 
t~'ally significant. The three groups did no~ differ with regard to treatment compliaace. 
D i s c u s s i o n  
Thirty-nine percent (17 of 44) of schizop~-enic patients were DST nonsuppressors at 
medication-free baseline. Four weeks after neuroleptic treatment, 14% (6 of 441 of these 
patients remained DST nonsuppressors. The rate of DST nonsuppression ob.,;erved in our 
sample is intermediate between the 0% to 73% reported in the literature and is comparable 
to data reported in most recent studies (Table 2). All studies of the t -rag DST in schizo- 
phrenia (not schizoaffective disorder) with a sample size >10,  wfuch employed a post- 
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Table 1. Comparison of Persistent DST Suppressors, Persistent DST Nonsuppressors, and DST 
Nonsuppressors Converting to Suppressor Status with Four Weeks Neuroleptic Treatment 
Persistent DST Normalizing DST Persistent DST 
suppressors nonsuppressors nonsuppressors Significance 
Parameter (S-S) n = 26 (NS-S) n = 12 (NS-NS) n = 6 (ANOVA) 
Age 27 -+ 8 32 --- 8 31 4- 7 NS 
Sex (M/F) 18 M/8 F 7 M/5 F 4 M/2 F NS 
VBR 0.077 ~ 0.03 0.080 --- 0.03 0.097 4- 0.05 NS 
Medication-free 
Positive (BPRS "THOT") t3.3 - 3.0 16.5 ~ 3.4 15.8 4- 1.0 NS 
Negative (SANS glob sum) 11.7 - 4.2 15.1 ~ 2.0 15.5 --- 1.9 F = 'L2;p <0.01 
Depression (HRSD tot) 13.1 4. 4.8 13.4 -* 2.7 12.3 -+ 3.4 NS 
Global severity (BPRS tot) 48.2 ± 7.4 50.5 ~ 9.0 49.0 4- 4.7 NS 
Post-dex cortisol ~g/dl 2. zt 4- 1.3 10.0 - 4.7 12.8 4. 6.8 p <0.001 
Four-weeks posttreatment 
Positive 9.6 - 3.1 8.8 ~ 2,9 10.2 - 3.8 NS 
Negative 8.3 - 4.0 8.8 ~ 3.0 12.0 4. 2.7 F = 3.3; p <0.05 
Depression 7.0 -+ 3.5 6.9 4. 2.4 6.7 ± 3.5 NS 
Global severity 35.5 4- 7.1 32.8 4- 5.9 37.7 4- 6.7 NS 
Post-dex cortisol 1.8 4- 0.8 1.8 _+ 0.8 8.7 4- 3.2 p <0.001 
Change in symptoms 4 weeks 
Positive 5.7 4. 3.3 7.7 + 4.7 5.7 ± 3.4 NS 
Negative 3.4 4. 2.0 6.3 ~':. 2.6 3.5 -+- 2.6 F = 6.5;p <0.01 
Depression 5.7 -+ 2.4 6.6 4. 1.7 5.7 --- 2.5 NS 
Global severity 12.7 - 6.8 17.7 ± 6.5 11.3 --- 5.2 F = 3.3;p <0.05 
One-year outcome 
Hospitalizatiofl 3.6 4. 0.~' 3.9 -+ 0.3 3.3 ~ 0.8 NS 
Employmen' 1.7 ~ 1.2 1.9 +- 0,9 1.0 ± 0.9 NS 
Social activity 2.3 4. 1.4 2.8 4- 1.5 2.0 4- 1.4 NS 
Symptoms 2.1 4- 1.0 2.0 - 0.8 1.3 4- 0.8 NS 
Global function 2.4 4- 1.1 2.7 -+ l . l  1.6 ± 0.9 NS 
Total 12.1 4- 2.0 13.3 4- 2.1 9.2 ± 1.7 F = 3.5; p <0.05 
Compliance 3.2 ± 1.1 3.1 ± 1.4 3.5 4- 0.8 NS 
dexamet.hasone cort iso! va lue  of  5 ;~g/dl as the cu tof f  for nonsuppress ion  are enumera t ed  
in this  table° A summary  meta -ana lys i s  o, ~ these s tudies  reveal.~; a DST  non~uppre~,~sion 
rate of  36% in the drag- f ree  stare (39% in our  sample)  and  20% ir~ the medica ted  state 
(14% in our  sample) .  These  data  sugges t  that  phase  of  fllnes:; and med ica t ion  status 
influence rates of  D S T  nons t , -p ress ion  in sch izophren ia  and m par t ia l ly  account  for 
the d iscrepant  f indings in the tt terature. Ra tes  o f  D S T  nonsuppress ion  are h igher  in drug-  
free schizophrenic  pat ients  in the acute  phase  of  the i l lness.  The  s ignif icant  reduct ion  in  
rates of  DST nonouppress ion that we  observed  after  3 - 4  weeks  o f  neuro lep t ic  t rea tment  
is cons is ten t  wi th  this  sugges t ion  and wi th  f indings of  other  s tudies  in  which  the DST  
was  Fefforme~ before  and af ter  neurolept ic  t rea tment  (Herz  et  al t985 ;  Ho l sboer -Trachs le r  
et  al 1987; Moi l e r  et  al  1986; Tandon  et al  1989a; W i k  et  al  1986). 
The  associa t ion  be tween  pos tdexamethasone  cor t isol  l eve l s  and  sever i ty  of  neg, ,dve 
s y m p t o m s  observed  in our  s tudy is in ag reement  wi th  e igh t  o f  the 12 o ther  s tudies  that  
eva lua ted  this  assoc ia t ion  (refer  to Table  2). W e  observed  an assoc ia t ion  be tween  post-  
dexamethasone  cor t isol  and nega t ive  s y m p t o m s  in the drug-free  state,  but  not  af ter  3 - 4  
weeks  of  neurolept ic  t reatment .  These  f indings are s imi la r  to those  o f  the Stanford g roup ,  
T a b l e  2 .  D e x a m e t h a s o n e  S u p p r e s s i o n  T e s t  i n  S c h i z o p h r e n i a :  R a t e s  o f  N o n s u p p r e s s i o n ,  
A s s o c i a t i o n  w i t h  S y m p t o m a t o l o g y ,  M e d i c a t i o n  S t a t u s ,  a n d  O u t c o m e  
N o n s u p p r e s s i o n  r a t e  A s s o c i a t i o n s  
S t u d y  M e d .  f r e e  M e d i c a t e d  N e g a t i - e  D e p r e s s i o n  O u t c o m e  
A d d i n g t o n  a n d  A d d i n g t o n  1 9 9 0  - -  6 / 5 0 ( 1 2 % )  N o  Y e s  
A l e e m  e t  a l  1 9 8 8  - -  6 / 1 9 ( 3 2 % )  - -  N o  - -  
A l t a m n r a  e t  a l  1 9 8 9  - -  2 2 / 5 4 ( 4 0 % )  Y e s  - -  - -  
A s n i s  e t  a !  1 9 8 6  4 / 1 7 ( 2 4 % )  . . . .  
B a n k i  e t  a l  1 9 8 4  1 9 / 4 5 ( 4 2 % )  . . . . .  
B a n k i  e t  a l  1 9 8 6  7 / 2 0 ( 3 5 % )  . . . .  
B a u m g a r t n e r  e t  a l  1 9 8 5  1 1 / 2 2 ( 5 0 % )  . . . .  
B e r g e r  e t  a l  1 9 8 4  - -  4 / 2 1 ( 1 9 % )  - -  - -  - -  
C a s t r o  e t  al  1 9 8 3  - -  7 / 2 3 ( 3 0 % )  - -  - -  - -  
C o p p e n  e t  al  1 9 8 3  - -  1 0 / 4 6 ( 2 2 % )  Y e s  - -  - -  
C o r y e l l  a n d  Z i m m e r m a n  1 9 8 9  - -  8 / 3 1  ( 2 6 % 1  - -  - -  g o o d  1 - y e a r  o u t c o m e  
D a m  e t  a l  1 9 8 5  - -  5 / 1 5 ( 3 3 % )  . . . .  
D e w a n  e t  a l  1 9 8 2  - -  6 / 2 0 ( 3 0 % )  - -  N o  - -  
D o r a n  e t  a l  1 9 8 6  2 / 1 3 ( 1 6 % )  - -  - -  N o  - -  
F a n s t m a n  e t  al  1 9 9 0  7 / 2 1 ( 3 3 % )  - -  Y e s  N o  - -  
G o l d  e t  a l  1981 - -  0 / 2 5  ( 0 % )  - -  - -  - -  
H a r r i s  1 9 8 5  - -  4 / 1 2 ( 3 3 % )  Y e s  - -  - -  
H e r z  e t  a l  1 9 8 5  1 1 / 1 5 ( 7 3 % )  1/5  ( 2 0 % )  - -  - -  - -  
H o l s b o e r - T r a c h s l e r  e t  a l  1 9 8 7  15 /31  ( 4 8 % )  4 / 3 1  ( 1 3 % )  - -  - -  n o t  re ia teA:  4 w e e k s  
H u b a i n  e t  a~ 1 0 ~ 6  1 0 1 2 2 ( 4 5 % )  . . . .  
H w a n g  e t  a l  t 9 8 4  - -  2 / 1 3 ( 1 5 % )  - -  - -  - -  
J o n e s  e t  a l  1 9 9 0  6 / 1 7 ~ 3 5 % )  - -  N o  Y e s  - -  
J o s e p h  e t  a l  1 9 8 7  - -  2 / 3 9  ( 5 % )  - -  - -  - -  
K e s h a v a n  e t  al  1 9 8 9  3 / 2 7 ( 1 1 % )  N o  N o  w o r s e  o u t c o m e ;  4 
w e e k s  
K i r i i k e  e t  a l  1 9 8 8  - -  2 / 2 2  ( 9 % )  - -  - -  - -  
K r i s h n a n  e t  al  1 9 8 7  - -  2 / 1 5 ( 1 3 % )  - -  N o  - -  
M c O a u l e y  e t  a l  1 9 8 9  - -  4 / 2 8 ( 1 4 % )  Y e s  N o  - -  
M c M a h o n  e t  a l  1 9 8 6  - -  2 / 1 2 ( 1 7 % )  - -  - -  - -  
M e l l s o p  e t  a l  1985  6 / 3 0 ( 2 0 % )  . . . .  
M o i l e r  e t  al  1 9 8 6  1 2 / 2 0 ( 6 0 % )  6 / 1 3 ( ~ 6 % )  - -  - -  - -  
M o r p h y  e t  al  1 9 8 5  - -  6 / 1 3 ( 4 6 % )  - -  - -  - -  
M u n r o  e t  a l  1 9 8 4  - -  7 / 4 6 ( 1 5 % )  - -  Y e s  - -  
N e l s o n  e t  al  1 9 8 4  - -  4 / ! 4 ( 2 9 % )  . . . . .  
N i s h i m o n  e t  al  1 9 8 4  - -  1 6 / 6 7 ( 2 5 % )  . . . .  
P a n d e y  e t  al  1 9 8 7  4 / 2 2 ( 1 8 % )  . . . .  
P e r e n y i  e t  al  1 9 8 7  - -  6 / 3 0 ( 2 0 % )  - -  N o  - -  
R i h m e r  a n d  A r a t o  1 9 8 4  - -  1 / 2 0  ( 5 % )  - -  - -  - -  
R o t h s c h i l d  e t  al  1 9 8 2  - -  2 / 1 4 ( 1 4 % )  . . . .  
S a f f e r  e t  a l  1 9 8 5  - -  1 0 / 5 0 ( 2 0 % )  Y e s  N o  - -  
S a w y e r  a n d  J e f f r i e s  1 9 8 4  - -  7 / 2 0 ( 3 5 % )  - -  Y e s / N o  - -  
S c h l e s s e r  e t  al  t , )80 - -  0 / 4 8  (f~%) - -  - -  - -  
S h a r m a  e t  al  1 9 8 8  8 / 4 4 ( 1 8 % ,  - -  - -  N o  - -  
S h i m a  e t  a l  1 9 8 6  - -  5 / 2 2 ( 2 3 % )  Y e s  N o  - -  
S i r i s  e t  a l  1 9 8 4  - -  0 / t 6 ( 0 % )  - -  - -  - -  
S o r a  e t  al  1 9 8 6  - -  7 / 2 8 ( 2 5 % )  - -  - -  - -  
S t o k e s  e t  al  1 9 8 4  2 / 1 2 0 7 % )  . . . . .  
T a n d o n  e t  al  1 9 8 9  7 / 2 0 ( 3 5 % )  0 t 2 0 ( 0 % )  Y e s  N o  g o o d  o u t c o m e .  4 
w e e k s  
T a r g u m  1 9 8 3  5 / 2 1 ( 2 4 % )  ~ - -  - -  g o o d  o u t c o m e  5 
m o n t h s  
W h i t e f o r d  e t  a I  1 9 8 8  - -  9 / 4 0 ( ~ 3 % )  N o  N o  - -  
W i k  e t  al  1 9 8 6  1 5 / 2 1 ( 7 1 % )  3 / 1 5 ( 2 0 % )  . . . .  
W o l k o w i t z  e t  al  1 9 8 9  4 / 1 6 ( 2 5 % )  . . . .  
Z h o u  e t  a l  1 9 8 7  - -  6 / 4 8 ( 1 3 % )  . . . .  
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who observed no relationship between postdexamethasone cortisol and negative symptoms 
in chronic, medicated schizophrenic patients (Whiteford et al 1988), but observed such 
a relationship in acute, unmedicated patients (Faustman et a11990). These data, in addition 
to the association between postdexamethasone cortisol levels and change in negative 
symptoms observed in ou~" study, may indicate that in the acute phase of the illness, 
postdexamethasone cortisol levels are related to nonenduring negative symptoms (Car- 
penter et al 1988; Tandon et al 1990; Tandon and Greden 1990a). 
Our failure to find any association between postdexamethasone cortisol and depressive 
symptoms is consistent with the findings of 13 of the 17 studies tbat assessed this 
association (refer to Table 2). Despite the phenomenological overlap between negative 
and depressive symptoms and consequent difficulty in differentiating between them (Som- 
mers 1985; Addington and Addington 1990), recent studies indicate that these phenomena 
can be distinctly measured in schizophrenia (Barnes et al 1989; Newcomer et al 1990; 
Liberzon et al 1990). Our finding of an association between postdexamethasone cortisol 
levels and negative symptoms, but not with depressive symptoms, would support this 
contention. We found no other relationship between postdexamethasone co_rtisol and 
global severi~', a finding consistent with other studies that evaluated this association 
(Dewan et al 1982; Shima et al 1986; Tandon et al 1989a). 
The observed relationship between DST findings and outcome was complex. Baseline 
postdexamethasone cortisol itself was unrelated to outcome at 4 weeks or 1 year. The 
pattern of baselipe DST nonsuppression converting to normal suppression after 4 weeks 
of neuroleptic treatment was associated with significantly greater improven,ent in both 
negative symptoms and global severity at 4 weeks; this finding is consistent with our 
previous finding (Tandon et al 1989a) and those of Holsboer-Trachsler et al (1987). 
Conversely, persistent DST nonsuppressicn was associated with greater negative symptom 
severity at 4 weeks and poor outcome at 1 year. These findings parallel those in major 
depression, where normalizing baseline DST nonsuppression is associated with greater 
clinical improvement (Greden et al 1983; Brown and Quails 1981; Baldessai-Jni and Arana 
1985), and persistent DST nonsuppression is associated with poor outcome (Greden et 
al 1983; Baldessarini and Arana 1985). 
Our findings appear to be at variance with those of CoD, ell and Zimmerman (1989); 
they observed an association between baseline DST nonsuppression and good 1-year 
outcome in functional psychosis, including schizophrenia. The following methodological 
differences may have contributed to this discrepancy: (1) in their study, the baseline DST 
was not always performed under drug-free conditions; (2) the association between post- 
dexamethasone cortiso! levels and good l-year outcome noted in their study was somewhat 
equivocal with regard to the schizophrenic group (Tandon et al 1989b), and (3) because 
they were studying the association of baseline drug-free DST, their group of initial DST 
nonsuppressors included both normalizing nonsuppressors (associated with better 4-week 
outcome in our study) and persistent DS'I nonsuppressors (associated with worse 1-year 
outcome in our study). 
Pathophysiological mechanisms that may underly these phenomena are not known. Nor- 
malizing DST nonsuppression may be related to stress, cholinergic hyperactivity (Carroll 
et al 1980; Tandon arid Greden 1989, 1990b), or some other mechanism associated with 
better resolution of the index psychotic episode. The association between negative symp- 
toms and postdexamethasone cortisol at drug-free baseline, but not at 4-weeks posttreat- 
ment is consistent with this suggestion (Tandon and Greden 1989, 1990b). The greater im- 
provement in negative symptoms with 3-4 weeks of neumlepfic treatment in the normalizing 
DST nonsuppressor group and other data indicating that postdexamethasone cortisol levels 
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are related to nonendudng negative symptoms in the acute phase would also support this 
hypothesis. On the other hand, persistent DST nonsuppression may be related to some other 
mechanism (such as enlarged ventricles, Rothschild et al 1989) that may be associated with 
poor outcome (Coppen et al ! 983). In the present study, the persistent DST nonsuppressor 
group tended to have greater VBR (although this difference was not statistically significant, 
perhaps related 1o the small number of  patients in this group, n = 6) and poor 1-year out- 
come. However, these explanations remain speculative. 
In summary, a significant proportion of  schizophrenic patients exhibit abnormal feed- 
back regulation in the hypothalamic-pituitary-adrenal axis, as reflected in DST non- 
suppression. A greater proportion of  schizophrenic patients exhibit DST nonsuppression in 
the medication-free phase than in the neuroleptic-treated phase. There is a significant as- 
sociation between postdexamethasone cortisol and severity of  negative symptoms, partic- 
ularly in the drug-free phase. There appears to be no association between DST findings in 
schizophrenia and severity of  depressive symptoms. Normalizing DST nonsuppression ap- 
pears to be associated with greater clinical improvement with neuroleptic treatment. Per- 
sistent DST nonsuppression appears to be associated with worse outcome. While dist;,nc~ 
mechanisms may underlie these phenomena, the pathophysiological bases of  DST non- 
suppressk, n in schizophrenia remain unclear. Future studies should take medication status 
and phase of  illness into consideration, as these appear to be important confounding vari- 
ables. 
Supported in part by grants from the National Alliance for Schizophrenia and Depression (NARSAD) and NIH 
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